Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Rosenwald Lindsay A MdOwnership Type:Direct OwnershipSecurities:Common Stock, $0.0001 par valueNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:10,000Price:$3.04
-
Mar 22, 2024 (filed on Mar 25, 2024)Insider Name:Maraoui ClaudeOwnership Type:Direct OwnershipSecurities:Common Stock, $0.0001 par valueNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:10,000Price:$3.48
-
Mar 22, 2024 (filed on Mar 25, 2024)Insider Name:Smith Justin AdamOwnership Type:Direct OwnershipSecurities:Common Stock, $0.0001 par valueNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:30,000Price:$3.47
-
Mar 22, 2024 (filed on Mar 25, 2024)Insider Name:Rosenwald Lindsay A MdOwnership Type:Direct OwnershipSecurities:Common Stock, $0.0001 par valueNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:20,000Price:$3.40
-
Feb 22, 2024 (filed on Feb 23, 2024)Insider Name:Benesch JosephOwnership Type:Direct OwnershipSecurities:Common Stock, $0.0001 par valueNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,450Price:$3.75
-
Nov 28, 2023 (filed on Nov 29, 2023)Insider Name:Paley JeffreyOwnership Type:Direct OwnershipSecurities:Common Stock, par value $0.0001 per shareNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,745Price:$5.22
-
Nov 08, 2023 (filed on Dec 08, 2023)Insider Name:Paley JeffreyOwnership Type:Direct OwnershipSecurities:Common Stock, par value $0.0001 per shareNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-255Price:$3.76
-
Nov 07, 2023 (filed on Dec 08, 2023)Insider Name:Paley JeffreyOwnership Type:Direct OwnershipSecurities:Common Stock, par value $0.0001 per shareNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,245Price:$3.48
-
Oct 13, 2023 (filed on Oct 17, 2023)Insider Name:Smith Justin AdamOwnership Type:Direct OwnershipSecurities:Common Stock, par value $0.0001 per shareNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:33,000Price:$2.98
-
Oct 06, 2023 (filed on Oct 10, 2023)Insider Name:Paley JeffreyOwnership Type:Direct OwnershipSecurities:Common Stock, par value $0.0001 per shareNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:15,000Price:$2.98
Filings by filing date
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Rosenwald Lindsay A MdOwnership Type:Direct OwnershipSecurities:Common Stock, $0.0001 par valueNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:10,000Price:$3.04
-
Mar 22, 2024 (filed on Mar 25, 2024)Insider Name:Maraoui ClaudeOwnership Type:Direct OwnershipSecurities:Common Stock, $0.0001 par valueNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:10,000Price:$3.48
-
Mar 22, 2024 (filed on Mar 25, 2024)Insider Name:Smith Justin AdamOwnership Type:Direct OwnershipSecurities:Common Stock, $0.0001 par valueNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:30,000Price:$3.47
-
Mar 22, 2024 (filed on Mar 25, 2024)Insider Name:Rosenwald Lindsay A MdOwnership Type:Direct OwnershipSecurities:Common Stock, $0.0001 par valueNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:20,000Price:$3.40
-
Feb 22, 2024 (filed on Feb 23, 2024)Insider Name:Benesch JosephOwnership Type:Direct OwnershipSecurities:Common Stock, $0.0001 par valueNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,450Price:$3.75
-
Nov 08, 2023 (filed on Dec 08, 2023)Insider Name:Paley JeffreyOwnership Type:Direct OwnershipSecurities:Common Stock, par value $0.0001 per shareNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-255Price:$3.76
-
Nov 07, 2023 (filed on Dec 08, 2023)Insider Name:Paley JeffreyOwnership Type:Direct OwnershipSecurities:Common Stock, par value $0.0001 per shareNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,245Price:$3.48
-
Nov 28, 2023 (filed on Nov 29, 2023)Insider Name:Paley JeffreyOwnership Type:Direct OwnershipSecurities:Common Stock, par value $0.0001 per shareNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,745Price:$5.22
-
Oct 13, 2023 (filed on Oct 17, 2023)Insider Name:Smith Justin AdamOwnership Type:Direct OwnershipSecurities:Common Stock, par value $0.0001 per shareNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:33,000Price:$2.98
-
Oct 06, 2023 (filed on Oct 10, 2023)Insider Name:Paley JeffreyOwnership Type:Direct OwnershipSecurities:Common Stock, par value $0.0001 per shareNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:15,000Price:$2.98
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 9237 E Via De Ventura Blvd. Suite 105, Suite 105 SCOTTSDALE AZ 85258 |
Tel: | 1-781-6524500 |
Website: | https://journeymedicalcorp.com |
IR: | See website |
Key People | ||
Lindsay A. Rosenwald Executive Chairman of the Board | Claude Maraoui President, Chief Executive Officer, Director | Joseph Benesch Interim Chief Financial Officer, Corporate Controller | Ramsey Alloush General Counsel, Corporate Secretary |
Business Overview |
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes seven branded and two authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved by the United States Food and Drug Administration (FDA) for sale, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox and Luxamend. It sells two authorized generic products, including sulconazole nitrate cream and solution and doxycycline hyclate immediate release 50mg tablets. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. |
Financial Overview |
For the fiscal year ended 31 December 2023, Journey Medical Corp revenues increased 7% to $79.2M. Net loss decreased 87% to $3.9M. Revenues reflect Accutane segment increase of 10% to $20.2M, Other branded revenue segment increase from $0K to $35K. Lower net loss reflects Selling, general and administra decrease of 25% to $41.4M (expense), Research and development - Balancing val decrease of 32% to $7.4M (expense). |
Employees: | 58 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $37.55M as of Dec 31, 2023 |
Annual revenue (TTM): | $79.18M as of Dec 31, 2023 |
EBITDA (TTM): | $4.84M as of Dec 31, 2023 |
Net annual income (TTM): | -$3.85M as of Dec 31, 2023 |
Free cash flow (TTM): | $0.24M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 19,932,310 as of Mar 28, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |